AOD-9604:
The Fat-Regulating Fragment of Human Growth Hormone

Derived from

hGH amino acids 177–191 (C-terminal fragment), modified with N-terminal tyrosine

Developed by

Monash University, Australia; clinical trials conducted through Phase 2/3

Regulatory status

FDA GRAS (Generally Recognized as Safe) designation

Primary mechanism

Beta-3 adrenergic receptor agonism on adipocytes → lipolysis stimulation, lipogenesis inhibition

Key distinction from full hGH

Does not stimulate IGF-1, does not promote tissue growth, does not affect blood glucose

Delivery formats

Subcutaneous injectable, oral troche

Beta-3 Adrenergic Receptor Agonism: Targeted Lipolysis

AOD-9604 binds to beta-3 adrenergic receptors (beta-3 AR) expressed on white and brown adipocytes. Beta-3 AR activation triggers lipolysis, the enzymatic breakdown of stored triglycerides into free fatty acids and glycerol, releasing them from adipose tissue into circulation for oxidation. Simultaneously, AOD-9604 inhibits lipogenesis, the synthesis of new triglycerides from circulating fatty acids and glucose. The net effect is a shift in the fat storage-to-release balance: the adipocyte is releasing more and storing less. This is the same mechanism through which the C-terminal fragment of full hGH regulates adipose tissue, now delivered in isolation.

No IGF-1 Stimulation, No Growth Axis Engagement

Full hGH stimulates IGF-1 production by binding to the growth hormone receptor (GHR) via its N-terminal domain, a region not present in AOD-9604. AOD-9604 does not bind GHR, does not stimulate IGF-1, and does not produce the anabolic tissue effects (muscle growth, organ enlargement, fluid retention) associated with hGH or IGF-1 elevation. This is a clinically significant distinction for patients who want the fat-regulatory effects of GH signaling without the growth-axis activation, and for patients for whom elevated IGF-1 is a clinical concern.

No Effect on Blood Glucose or Insulin Sensitivity

One of the primary clinical limitations of therapeutic hGH use is its diabetogenic effect: full hGH reduces insulin sensitivity and can elevate fasting glucose, complicating its use in patients with metabolic risk factors. AOD-9604 does not bind insulin receptors, does not affect glucose uptake pathways, and has been demonstrated in clinical trials to have no effect on blood glucose or insulin levels. This makes it usable in patients where full hGH or IGF-1-elevating secretagogues carry metabolic risk.

Visceral vs. Subcutaneous Fat

Beta-3 adrenergic receptors are expressed at higher density in visceral adipose tissue, the metabolically active fat depot that accumulates around the abdominal organs and is most strongly associated with cardiometabolic risk. AOD-9604's lipolytic effect is therefore preferentially active on visceral fat, though subcutaneous fat reduction is also documented with sustained use. For patients whose primary concern is abdominal adiposity, this receptor distribution is clinically relevant.

Troche Bioavailability

The oral troche format delivers AOD-9604 via buccal absorption: the peptide is absorbed through the mucosal tissue of the mouth rather than passing through the gastrointestinal tract, which would degrade it. Buccal absorption bypasses first-pass hepatic metabolism and provides direct systemic delivery. Bioavailability via the troche route is lower than subcutaneous injection, making it appropriate for patients who prefer a non-injection option and are comfortable with a lower-potency delivery format, or as an adjunct to injectable protocols.

Patients who want the lipolytic effects of growth hormone signaling, without IGF-1 elevation, tissue growth, fluid retention, or blood glucose disruption, now have a targeted option. AOD-9604 delivers the fat-regulatory fragment of hGH's mechanism in isolation.

The beta-3 adrenergic receptor density of visceral adipose tissue means AOD-9604's lipolytic activity is preferentially targeted at abdominal fat, the fat depot most associated with insulin resistance, cardiovascular risk, and inflammatory disease.

The absence of IGF-1 stimulation and blood glucose effects makes AOD-9604 available to patients for whom hGH-stimulating secretagogues carry elevated metabolic risk, including patients with pre-diabetes, insulin resistance, or clinical caution around IGF-1 elevation.

The injectable vial provides maximal bioavailability for patients comfortable with subcutaneous injection. The troche provides a no-injection alternative for patients who prefer it, or serves as a convenient adjunct for travel days or injection-light periods.

AOD-9604 anchors the AOD/MOTS-C/Tesamorelin/Ipamorelin blend, a single injectable that pairs AOD-9604's direct lipolysis with MOTS-C's mitochondrial metabolic activation, Tesamorelin's GH-driven visceral fat reduction, and Ipamorelin's pulsatile GH amplification.

Patients with Stubborn Abdominal or Visceral Adiposity

Patients who are otherwise metabolically active and diet-compliant but carry persistent central fat that resists reduction through lifestyle alone. The beta-3 AR density of visceral adipose tissue makes AOD-9604 particularly effective for this fat depot specifically.

Patients Who Cannot Use IGF-1-Elevating Compounds

Patients with personal or family history of certain cancers, elevated baseline IGF-1, or clinical caution around growth factor stimulation may be ineligible for secretagogue protocols that elevate IGF-1. AOD-9604 provides a lipolytic option in this population without engaging the growth axis at all.

Metabolically Sensitive Patients: Pre-Diabetes, Insulin Resistance

Full hGH and IGF-1-elevating compounds can worsen insulin sensitivity. AOD-9604 has no blood glucose effects, and its clinical trial data confirmed no impact on fasting glucose or insulin levels. For patients already managing blood sugar, this is a meaningful clinical distinction.

Patients on GLP-1 Protocols Seeking Peptide Adjuncts

Patients using semaglutide or tirzepatide for weight loss who want to add a mechanistically distinct fat-targeted peptide to their protocol. GLP-1 agonists work primarily through appetite and insulin regulation; AOD-9604 works directly on adipocyte lipolysis via a completely independent pathway.

Injection-Averse Patients Who Still Want AOD-9604 Activity

The troche format provides an accessible entry point for patients who want AOD-9604's fat regulatory effects without subcutaneous injection. Bioavailability is lower than injectable but clinically meaningful, particularly as part of a comprehensive protocol.

Patients Building a Comprehensive Weight Loss Stack

The four-compound blend (AOD-9604, MOTS-C, Tesamorelin, Ipamorelin) is designed for patients who want to address fat loss from lipolytic, mitochondrial, GH-axis, and visceral fat reduction angles simultaneously. This page is the canonical home for that formulation.

Injectable Dosing

Standard dosing for the 1.2mg/mL (5mL) injectable is 300mcg subcutaneously once daily, typically administered in the morning in a fasted state to maximize lipolytic activity during the post-injection window. Some protocols use twice-daily dosing (morning and pre-workout); your provider will advise on the appropriate frequency and timing for your goals.

Troche Dosing

The 300mcg troche is dissolved sublingually or buccally, held under the tongue or against the inner cheek for full absorption. Once daily, typically morning. The troche delivers AOD-9604 via mucosal absorption, bypassing GI degradation while providing a lower-bioavailability alternative to subcutaneous injection. Do not swallow the troche; buccal/sublingual dissolution is required for meaningful absorption.

Fasted Administration

AOD-9604 is most effective when administered in a fasted state, ideally first thing in the morning before eating. Insulin elevation from a recent meal suppresses lipolytic signaling and reduces the net effect of AOD-9604's beta-3 AR activation. At minimum, a 2-hour fast prior to dosing is recommended.

Cycle Structure

AOD-9604 is typically run in 3-month continuous cycles followed by a structured rest period, though protocols vary. Because it does not affect the growth axis or insulin sensitivity, it has fewer contraindications for extended use than hGH-stimulating compounds. Your provider will establish cycle length and rest periods appropriate for your protocol.

Stacking Considerations

AOD-9604 is the anchor of the four-compound metabolic blend (with MOTS-C, Tesamorelin, and Ipamorelin) for patients targeting comprehensive fat loss. Standalone AOD-9604 pairs naturally with MOTS-C (AMPK-driven mitochondrial fat oxidation), with Tesamorelin (GH-driven visceral fat reduction through a complementary pathway), and with CJC-1295/Ipamorelin for patients who want GH axis stimulation alongside direct lipolysis.

AOD-9604 1.2mg/mL, 5mL Injectable

300mcg subcutaneous daily dosing, supporting a full 20-day protocol per vial. Maximum bioavailability format. Fasted morning administration. Syringes and alcohol swabs included.

$191.67

Subcutaneous Injection

• Async telehealth provider consultation
• Prescription fulfillment through Optimal Balance Pharmacy
• FedEx Standard Overnight shipping
• Syringes and alcohol swabs

AOD-9604 300mcg Troche

Buccal/sublingual dissolution, no injection required. Absorbed through oral mucosa, bypassing GI degradation. Lower bioavailability than injectable; appropriate for injection-averse patients or as a protocol adjunct.

$119.00

Oral Troche (Buccal/Sublingual)

• Async telehealth provider consultation
• Prescription fulfillment through Optimal Balance Pharmacy
• FedEx Standard Overnight shipping

AOD-9604 / MOTS-C / Tesamorelin / Ipamorelin Blend, 5mL

Four-compound metabolic stack: AOD-9604 1.2mg/mL + MOTS-C 2mg/mL + Tesamorelin 2mg/mL + Ipamorelin 2mg/mL. Four mechanistically distinct fat-reduction pathways in a single daily injection. Syringes and swabs included.

$266.67

Subcutaneous Injection

• Async telehealth provider consultation
• Prescription fulfillment through Optimal Balance Pharmacy
• FedEx Standard Overnight shipping
• Syringes and alcohol swabs